Corticobasal degeneration with progressive supranuclear palsy syndrome: a clinical case

Background. Corticobasal degeneration (CBD) is a sporadic disorder of tau protein metabolism with an incidence of approximately 4–7 cases per 100,000 people. CBD is characterized by a gradual onset and steady progression, as well as a combination of various combinations of characteristic clinical signs, such as asymmetric akinetic-rigid syndrome with insufficient response to levodopa therapy, apraxia, aphasia, specific “alien limb” phenomenon, cognitive impairment with asymmetric cortical atrophic changes according to MRI of the brain. Considering that the group of tauopathies, in addition to CBD, includes progressive supranuclear palsy (PSP), Alzheimer’s disease and other diseases, and a combination of this pathology is often observed, as a result of this the clinical picture can be quite variable. Therefore, neurodegenerative changes in the cortical-subcortical structures in combination with various pathologies with a characteristic clinical picture are included in the concept of corticobasal syndrome.

Сlinical Сase Description. The article presents a clinical case of corticobasal degeneration combined with progressive supranuclear palsy syndrome in a 69-year-old woman.

Conclusion. Today, when making a diagnosis, it is necessary to take into account not only the clinical picture as a whole, but also the features of its development. An important problem is that corticobasal degeneration with progressive supranuclear palsy is difficult to diagnose, especially in the early stages of the disease, and treatment with antiparkinsonian drugs is ineffective.

1. Singleton А., Hague S. X-linked recessive dystonia parkinsonism. Adv.Neurol. 2004; 94: 139–142.

2. Extrapyramidal syndromes: A guide for doctors / O. S. Levin, S. N. Illarioshkin, V. L. Golubev. Moscow: MEDpress-inform, 2022. 772 p.: ill. (In Russ.).

3. Strang K. H., Croft C. L., Sorrentino Z. A. Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies. Journal of Biological Chemistry, 2018; 293 (7): 2408–2421.

4. Shpilyukova Yu.A., Fedotova E. Yu., Illarioshkin S. N. Corticobasal syndrome as a phenotypic manifestation of various neurodegenerative diseases: description of a case series. Annals of Clinical and Experimental Neurology. 2022; 16(1): 64–70. (In Russ.).

5. Armstrong M. J., Litvan I., Lang A. E. et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013; 80 (5): 496–503.

6. Togasaki D. M., Tanner C. M. Epidemiologic aspects / In: Corticobasal degeneration and related disorders. Philadelphia, 2000. P. 53–60.

7. Arienti F., Lazzeri G., Vizziello M. et al. Unravelling genetic factors underlying corticobasal syndrome: a systematic review. Cells. 2021; 10 (1): 171.

8. Tappakhov A. A., Popova T. E., Govorova T. G., Petrova A. Yu. Clinical heterogeneity of progressive supranuclear palsy. Annals of Clinical and Experimental Neurology. 2018; 12 (2): 33–38. (In Russ.).

9. Im S. Y., Kim Y. E., Kim Y. J. (2015). Genetics of Progressive Supranuclear Palsy. Journal of Movement Disorders. 8 (3): 122–129.

10. Boxer A. L., Yu J.-T. Golbe Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. The Lancet Neurology. 2017; 16 (7): 552–563.

11. Höglinger G. U., Litvan I. Mendonca Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. The Lancet Neurology. 2021; 20 (3): 182–192.